Physician profile
Cheryl Scholes
NPI 1184952822
$5,286.08
in general payments reported to CMS, 2019-2025
50 companies · $62.68 in 2025
The $62.68 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,268 · 2022: $1,166 · 2023: $1,603 · 2024: $186 · 2025: $62.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.46 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.63 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $833.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $341.50 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $327.08 | 2021-2025 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $240.37 | 2021-2023 | Wegovy |
| Lilly USA, LLC | $224.59 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $215.06 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $201.33 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.53 | 2021-2023 | Jardiance |
| Antares Pharma, INC. | $118.37 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Nestle Healthcare Nutrition INC. | $112.52 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.93 | 2021-2024 | Trulance, Xifaxan |
| Axsome Therapeutics, INC. | $106.59 | 2022-2023 | Sunosi, Auvelity |
| Supernus Pharmaceuticals, INC. | $105.91 | 2021-2023 | Qelbree, Xyosted |
| Boston Scientific Corporation | $103.19 | 2021-2025 | Wavewriter Alpha Prime 16 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Scholes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.